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Abstract
Invariant NKT (iNKT) cells are involved in the pathogenesis of various infectious diseases. However, their role in hepatitis B
virus (HBV) infection is not fully understood, especially in human species. In this study, 35 chronic hepatitis B (CHB) patients,
25 inactive carriers (IC) and 36 healthy controls (HC) were enrolled and the proportions of circulating iNKT cells in fresh
isolated peripheral blood mononuclear cells (PBMC) were detected by flow cytometry. A longitudinal analysis was also
conducted in 19 CHB patients who received antiviral therapy with telbivudine. Thereafter, the immune functions of iNKT
cells were evaluated by cytokine secretion and a two-chamber technique. The median frequency of circulating iNKT cells in
CHB patients (0.13%) was lower than that in HC (0.24%, P=0.01) and IC (0.19%, P=0.02), and increased significantly during
antiviral therapy with telbivudine (P=0.0176). The expressions of CC chemokine receptor 5 (CCR5) and CCR6 were
dramatically higher on iNKT cells (82.83%69.87%, 67.67%616.83% respectively) than on conventional T cells
(30.5%65.65%, 14.02%65.92%, both P,0.001) in CHB patients. Furthermore, iNKT cells could migrate toward the CC
chemokine ligand 5. Patients with a high ratio ($1.0) of CD42/CD4+ iNKT cells at baseline had a higher rate (58.33%) of
HBeAg seroconversion than those with a low ratio (,1.0, 0%, P=0.0174). In conclusion, there is a low frequency of
peripheral iNKT cells in CHB patients, which increases to normal levels with viral control. The ratio of CD42/CD4+ iNKT cells
at baseline may be a useful predictor for HBeAg seroconversion in CHB patients on telbivudine therapy.
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Introduction
Worldwide, more than 300 million people suffer from chronic
hepatitis B virus (HBV) infection, leading to a wide spectrum of
liver diseases including chronic hepatitis B (CHB), cirrhosis, and
hepatocellular carcinoma [1]. The pathogenesis of CHB and
cirrhosis is thought to be mediated by the immune response to the
HBV rather than the HBV itself [2]. Multiple types of immune
cells and molecules are involved in HBV associated liver damage.
However the precise roles of these cells and molecules are still
incompletely understood.
Invariant NKT (iNKT) cells are a unique group of T
lymphocytes that express an identical T cell antigen receptor
(TCR) a chain, Va14-Ja18 in mice and Va24-Ja18 in humans [3].
iNKT cells differ from conventional T lymphocytes in that they
recognize lipid or glycolipid antigens presented by the MHC class
I-like molecule CD1d. When activated with CD1d tetramer or
anti-CD3, iNKT cells rapidly secrete a variety of Th1 and Th2
cytokines within a few hours [4]. Although iNKT cells comprise a
very small proportion of peripheral T cells, about 1% in mice and
0.2% in humans, they seem to play important roles in regulating a
number of immune responses, including transplant rejection,
cancer, autoimmunity, allergy, and infection [5,6].
The liver contains a larger number of iNKT cells relative to
blood and other lymphoid organs [7,8,9]. Increasing evidence
suggests that iNKT cells contribute to a variety of liver disorders,
including drug-induced liver injury [10,11], primary biliary
cirrhosis [12,13], alcoholic liver injury [14], autoimmune hepatitis
[15], hepatocellular carcinoma [16], non-alcoholic fatty liver
disease [17], and viral hepatitis [18,19]. In CHB, alpha-
galactosylceramide (a-GalCer) activated iNKT cells are able to
inhibit HBV replication in vivo [20] and are implicated in the
pathogenesis of cirrhosis by producing profibrotic cytokines [21].
Activation of iNKT cells also promotes the loss of tolerance to
HBV-specific CD8+ T cell antigens [22]. However, most of these
reports are based on mouse models, and the role of iNKT cells in
CHB patients is largely unknown. There are few reports about the
changes in iNKT cell frequency or activity in CHB patients during
antiviral therapy.
In the present study, we compared the frequency of circulating
iNKT cells in 35 CHB patients, 25 inactive HBV carriers and 36
healthy individuals by flow cytometry. We also compared the
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iNKT cells to migrate toward different chemokines and the ability
to secret cytokines between CHB patients and healthy controls.
Finally, we analyzed the longitudinal changes of iNKT cells
frequency in CHB patients who received antiviral therapy with
telbivudine.
Methods
Ethics statement
The study protocol was conducted within the guidelines of the
1975 Declaration of Helsinki, and was approved by the ethics
committee of Nanfang Hospital. Written informed consent was
obtained from all subjects.
Patients
Thirty-five chronic hepatitis B (CHB) patients, 25 inactive HBV
carriers (IC) and 36 healthy controls (HC) were enrolled in the
present study. CHB patients and IC were diagnosed according to
the described criteria [23]. The basic clinical characteristics of all
subjects were listed in Table 1.The subjects with previous antiviral
therapy, with co-infection by the HIV, other hepatitis virus, and
with diabetes, severe systemic illness, regular alcohol consumption
and hepatocellular carcinoma were excluded.
Serological assays and HBV DNA assays
The presence of HBsAg, HBsAb, HBeAg, HBeAb and HBcAb
was determined using commercial AxSYM MEI kits (Abbott
Laboratories, North Chicago, IL). The HBV DNA level was
quantified by the Roche Diagnostics Cobas Taqman 48 (Meylan,
France), which has a detection limit of 300 HBV-DNA copies/ml.
Flow cytometry analysis
All the fluorochrome-conjugated antibodies with the isotype
controls were purchased from BD Biosciences Pharmingen (San
Jose, CA, USA) except for PerCP-anti-CD4 from BioLegend (San
Diego, CA, USA).
Ten to thirty milliliter (ml) of heparinized blood was collected
from all individuals at the time of recruitment. Of the CHB
patients, 19 received anti-viral therapy with telbivudine and were
followed up for at least 52 weeks, and additional blood samples
were obtained at week 12, week 24 and week 52 during the course
of therapy. Peripheral blood mononuclear cells (PBMC) were
isolated from whole blood by Ficoll density gradient centrifugation
using Lymphoprep
TM (AXIS-SHILD, Oslo, Norway). One million
fresh isolated PBMC were washed with phosphate-buffered saline
(PBS) and resuspended in 100 ml FACS buffer (PBS with 0.5%
FBS), and then stained with FITC-anti-CD3, APC-anti-CD4 and
PE-anti-iNKT (6B11) at room temperature (RT) for 20 min. After
that, cells were washed and analyzed using a BD FACS Canto II
cytometer (BD Biosciences, CA, USA) with FACSDiva 5.0 (BD
Bioscience, San Jose, CA) and FlowJo (Tree Star Inc., Ashland,
OR) software. At least 3 610
5 lymphocytes were gated for each
sample.
In some cases, the expression of CC chemokine receptor 5
(CCR5) and CCR6 on peripheral iNKT cells and other T cells
was also measured by flow cytometry.
Intracellular cytokine staining (ICS)
Intracellular cytokine production within peripheral iNKT cells
was determined by a four-color flow cytometry as described
previously with some modifications [24]. Briefly, two million fresh
isolated PBMC were suspended in 200 ml RPMI 1640 supple-
mented with 10% FBS, and stimulated with 200 ng/ml a-
galactosylceramide (a-GalCer, Enzo Life Sciences, NY, USA) or
in some cases with 50 ng/ml Phorbol 12-myristate 13-acetate
(PMA, Sigma-Aldrich, St. Louis, USA) plus 1 mM calcium
ionomycin (Sigma-Aldrich) for 1 hour at 37uC. Brefeldin A (BD
Biosciences) was added at 5 mg/ml, and incubation was continued
for an additional 8 hours for a-GalCer or 3 hours for PMA
stimulation. Cells were then harvested and washed with PBS, and
stained with cell surface markers by APC-Cy7-anti-CD3, PerCP-
anti-CD4 and PE-anti-iNKT for 20 minutes at RT. The stained
cells were washed, fixed and permeabilized with Fix&PermH
reagents (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. After that, the cells were incubated
with either Alexa Fluor 488-anti-IFN-c or FITC-anti- IL-4 for
20 minutes at RT. Cells were then washed and analyzed by flow
cytometry. At least 5 610
5 gated lymphocytes were collected for
each sample.
Migration assay
The ability of recombinant CC chemokine ligand 5 (CCL5) and
CCL20 to attract iNKT cells was examined using a transwell
system with 24-well and 5 mm pore size (Corning, NY, USA). One
and half million fresh isolated PBMC from 3 HC subjects were
added to the upper chamber, and either 500 ng/ml CCL5 or
CCL20 (PeproTech, NJ, USA) were added to the lower chamber.
After 10 hours incubation at 37uC, the cells in the lower chamber
were harvested and the frequency of iNKT cells was detected by
flow cytometry.
Statistical Analysis
All statistical tests were performed in GraphPad Prism 5
(GraphPad software, CA, USA). Comparisons between different
groups were performed using the Mann- Whitney U test. Within-
subject data were compared with the repeated measures ANOVA
followed by Tukey’s or Bonferroni post-tests. The Spearman rank
order correlation coefficient was used for correlation analyses.
Categorical variables were compared by Fisher’s exact test. The
area under receiver operating characteristics (ROC) curves were
calculated to assess the use of peripheral iNKT cells frequency at
baseline to predict HBeAg seroconversion. For all tests, a two-
sided P,0.05 was considered significant.
Table 1. Clinical characteristics of the subjects enrolled in the
study.
HC CHB IC
Cases (n) 36 35 25
Gender (male/female) 17/19 23/12 12/13
Age (years) 23.5 (21–34) 27 (19–38) 36 (22–55)
Log10 HBV DNA (copies/ml) ND 8.64 (6.19–9.9) ,3
ALT (U/L) ,40 173 (43–834) ,40
AST (U/L) ,40 88 (34–345) ,40
HBsAg positive 0 35 25
HBeAg positive 0 35 0
HBeAb positive 0 0 25
HBcAb positive 0 35 25
Note. Data were shown as median (range), unless otherwise noted. HBV,
hepatitis B virus; ALT, alanine aminotransferase; AST, aspartate transaminase;
ND, not determined.
doi:10.1371/journal.pone.0028871.t001
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PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e28871Figure 1. Peripheral invariant NKT (iNKT) cells decreased in CHB patients. Fresh isolated PBMC were stained with FITC-anti-CD3, APC-anti-
CD4, and PE-anti-iNKT (6B11), which specifically recognizes the complementarity determining region 3 (CDR3) of the invariant Va24-Ja18 T cell
receptor (TCR) chain, and analyzed by flow cytometry. CD3+6B11+ dot plots indicated iNKT cells, and CD4 was used to determine the subsets of iNKT
cells. (A) Representative dot plots of total, CD42 and CD4+ iNKT cells in peripheral blood from healthy controls (HC), CHB patients and inactive
carriers (IC). (B) Pooled data of the frequencies of total, CD42 and CD4+ iNKT cells in three groups. Horizontal bars indicated the median value of each
group. (C) The ratio of CD42/CD4+ iNKT in HC, CHB and IC. Horizontal lines illustrated the 25
th,5 0
th, and 75
th percentiles. (D, E) Spearman correlation
test showed that the frequencies of total iNKT cells in CHB patients (n=30) had no correlation with HBV DNA and alanine transaminase (ALT) levels. *
P,0.05, ** P,0.01, *** P,0.001, using the Mann-Whitney U test.
doi:10.1371/journal.pone.0028871.g001
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PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e28871Figure 2. Peripheral iNKT cells expressed high levels of CC chemokine receptor 5 (CCR5) and CCR6. (A) Representative dot plots of
CD3+6B11+ iNKT and CD3+6B11- T (Other T) cells from CHB patients (n=6) and histograms of CCR5 and CCR6 expression within each quadrant. (B, C)
Pooled data compared the expression of CCR5 and CCR6 between iNKT and other T cells, between CD42 and CD4+ iNKT cells from CHB patients.
*P,0.05, **P,0.01, using Mann-Whitney U test. (D) Schematic diagram of migration assay. Fresh isolated PBMC were added into the upper chamber,
500 ng/ml CC chemokine ligand 5 (CCL5), CCL20 or medium alone was added into the lower chamber. Ten hours later, the cells of the lower chamber
were harvested and analyzed. (E) Pooled data compared the percentages of iNKT cells in the lower chamber using paired t-test.
doi:10.1371/journal.pone.0028871.g002
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Circulating iNKT cells are decreased in CHB patients
We first compared the frequencies of peripheral iNKT cells in
subjects from the HC, CHB and IC groups. iNKT cellswere detected
by flowcytometry usinga monoclonalantibody 6B11(Fig. 1A), which
specifically reacts with the complementarity determining region 3
(CDR3) of the Va24-Ja18 T cell receptor of human iNKT cells [25].
We found that the frequency (medium, range) of iNKT cells in CHB
patients (0.13%, 0.027%–1.071%) was significantlylower than that in
HC (0.24%, 0.064%–0.81%, P=0.0143) and IC (0.19%, 0.06%–
0.38%, P=0.0235). By contrast, there was no significant difference
between HC and IC (P=0.703, Fig. 1B).
iNKT cells are heterogeneous and can be categorized into two
subsets according to the expression of CD4, namely CD4+ and
CD42 iNKT cells [26]. A comparison of the frequency of CD4+
and CD42 iNKT cells was performed in the three groups. We
found that the frequency of CD42 iNKT cells in CHB patients
(0.071%, 0.013%–0.98%) was decreased compared to HC
(0.175%, 0.027%–0.7%, P,0.01), and the frequency of CD42
iNKT cells in IC (0.072%, 0.019%–0.73%) was also significantly
lower compared to HC (P=0.023). There was no significant
difference (P=0.458) between CHB and IC in the frequency of
CD42 iNKT cells (Fig. 1B). By contrast, the frequency of CD4+
iNKT cells in CHB patients (0.053%, 0.007%–0.83%) was
Figure 3. Cytokine secretion of iNKT cells in CHB patients and healthy controls. Fresh isolated PBMC were stimulated with phorbol 12-
myristate 13-acetate (PMA) or a-galactosyl ceramide (a-GalCer), a CD1d-restricted antigen recognized specifically by iNKT cells, and the intracellular
cytokine were analyzed by flow cytometry. (A) The gating strategy of CD3+6B11+ iNKT cells and representative dot plots of interferon-gamma (IFN-c)
and interleukin-4 (IL-4) expression in iNKT cells from testing samples and isotype controls. (B) Pooled data showed the percentages of iNKT cells
producing IFN-c and IL-4 in response to a-GalCer (left) or PMA (right) in CHB patients and healthy controls. Comparisons between two groups were
performed using Mann- Whitney U test.
doi:10.1371/journal.pone.0028871.g003
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was similar to HC (0.055%, 0.01%–0.2%, P=0.7, Fig. 1B).
We next compared the ratio of CD42/CD4+ iNKT cells in the
different groups, and found that the ratio was decreased in CHB
patients (1.21, 0.11–10.77) relative to the HC (2.61, 0.53–9.55,
P,0.01), and even further decreased in the IC (0.78, 0.11–8.5)
relative to CHB (P=0.018, Fig. 1C). We also analyzed the
correlation between peripheral iNKT cells and plasma HBV DNA
load and serum alanine aminotransferase (ALT) level in the CHB
patients (n=30). The results indicated that there was no
Figure 4. Circulating iNKT cells of CHB patients were recovered during antiviral therapy. (A) Representative dot plots. (B–D) Pooled data
showing the dynamic changes of total, CD42 and CD4-iNKT cells at different time points in CHB patients (n=19) during antiviral therapy. * P,0.05,
** P,0.01, using repeated measures ANOVA followed by Tukey’s Multiple Comparison Test; NS, no significance.
doi:10.1371/journal.pone.0028871.g004
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HBV DNA load or serum ALT level (Fig. 1D and 1E). By contrast,
CD42 iNKT cells and the ratio of CD42/CD4+ iNKT cells were
negatively correlated with ALT levels (Fig. S1).
iNKT cells express high levels of CCR5 and CCR6
Next, we detected the expression of CCR5 and CCR6 on
peripheral iNKT cells in CHB patients (n=6) by flow cytometry
(Fig. 2A) and found that the proportion (mean6SD) of iNKT cells
expressing CCR5 (82.83%69.87%) or CCR6 (67.67%616.83%)
was dramatically higher than that of other T cells (CCR5,
30.5%65.65%, CCR6, 14.02%65.92%, both P,0.001, Fig. 2B).
Further analysis revealed that the percentage of CD42 iNKT cells
expressing CCR5 or CCR6 was also significantly higher than that
of CD4+ iNKT cells (P,0.05 and P,0.01 respectively, Fig. 2C).
Interestingly, the expression of CCR5 and CCR6 on iNKT cells
was comparable between CHB patients and HC subjects (Fig S2).
Our data above indicated that iNKT cells expressed higher
levels of CCR5 and CCR6 than other T cells. Therefore, we
performed a chemotaxis assay to test the hypothesis that CCL5
and CCL20, the ligands of CCR5 and CCR6 respectively, could
induce the migration of iNKT cells in vitro. We found that the
frequency of iNKT cells in the lower chamber in response to
CCL5 (0.87%60.24%) was significantly higher compared to
medium alone (0.65%60.23%, P,0.001). Surprisingly, the
frequency of iNKT cells in the lower chamber in response to
CCL20 was similar to medium alone (Fig. 2D and 2E).
Cytokine-secreting profile of iNKT cells in CHB patients
We also assessed the ability of iNKT cells to produce IFN-c and
IL-4 in response to the specific antigen a-GalCer and non-specific
mitogen PMA by flow cytometry. As shown in Fig. 3, the IFN-c
production of circulating iNKT cells in response to a-GalCer was
dramatically higher compared to IL-4, irrespective of whether they
were obtained from CHB patients or HC (both P,0.001).
Interestingly, there were no differences between the two groups
in both IFN-c (P=0.673) and IL-4 expression (P=0.8884). When
stimulated with PMA, there were also no significant differences
between CHB patients and HC in IFN-c and IL-4 production
(P=0.12, P=0.75 respectively). Surprisingly, the IFN-c response
to PMA was lower compared with the response to a-GalCer,
regardless of CHB patients or HC (both P,0.001). Taken
together, these data demonstrate that the ability of peripheral
iNKT cells to produce IFN-c and IL-4 is not impaired with
chronic HBV infection and IFN-c is the dominant cytokine
secreted by circulating iNKT cells in response to a-GalCer.
Decreased iNKT cell frequency recovers after telbivudine
therapy
We next analyzed the changes in peripheral iNKT cell
frequency in CHB patients on antiviral therapy (Fig. 4A). PBMC
were obtained at baseline and at week 12, 24 and 52 after
initiating treatment with telbivudine (n=19). We found that the
frequency of peripheral iNKT cells was significantly increased at
week 52 (0.21%, 0.05%–1.22%) compared with baseline (0.18%,
0.03%–1.07%, P=0.0176). At week 12 and week 24, the
frequency of circulating iNKT cells was also increased compared
to the baseline, but the difference did not reach statistical
significance (Fig. 4B). Further analysis indicated that the frequency
of CD42 but not CD4+ iNKT cells was dramatically increased by
week 52 (P,0.01, P=0.2898 respectively, Fig. 4C and 4D).
The ratio of CD42/CD4+ iNKT cells in CHB patients is
associated with HBeAg seroconversion
Of the 19 CHB patients treated with telbivudine, 7 (37%)
achieved HBeAg seroconversion by week 52. The plasma HBV
DNA load in patients with seroconversion decreased more rapidly
than patients not achieving seroconversion during the course of
therapy, especially after week 12 (Fig S3A). By contrast, both the
seroconversion and non-seroconversion patients had the similar
variation mode in serum ALT levels and circulating iNKT cells
(Fig S3B–F).
The precise mechanisms contributing to HBeAg seroconversion
during antiviral therapy are not fully understood. As showed in
Table 2, the patients who achieved HBeAg seroconversion tended
to have a slightly higher ratio of CD42/CD4+ iNKT cells (1.47,
1–3.56) compared to those who failed to achieve HBeAg
seroconversion (0.915, 0.11–3.4, P=0.0826). We also analyzed
this data by dividing the patients into high ($1) and low (,1) ratio
groups and found that the patients with a high ratio of CD42/
CD4+ iNKT cells at baseline were more likely to achieve HBeAg
serocon- version than those with a low ratio (P=0.02, Fig. 5A).
Next, a receiver operating characteristics (ROC) curve was
constructed to determine whether the ratio of CD42/CD4+
iNKT cells could be used as a predictor of HBeAg seroconversion
within 52 weeks of starting telbivudine therapy. The area under
the ROC curve (AUC) indicated the existence of a significant
association between the CD42/CD4+ iNKT ratio and HBeAg
Table 2. Baseline clinical characteristics of 19 CHB patients who received telbivudine.
Seroconversion at week 52 Non-seroconversion at week 52 P value
Cases (n) 7 12
Age (years) 26 (19–38) 27.5 (20–35) 0.6363
Gender (male/female) 4/3 9/3 0.6169
Log10 HBV DNA (copies/ml) 8.34(6.97–8.88) 8.77 (6.22–9.73) 0.5314
ALT (IU/L) 191 (87–270) 84.5 (43–335) 0.1837
CD42 iNKT/CD3+ T cells (%) 0.12 (0.041–0.17) 0.076(0.018–0.76) 0.3976
CD4+ iNKT/CD3+ T cells (%) 0.057 (0.04–0.097) 0.094 (0.004–0.83) 0.2906
Total iNKT/CD3+ T cells (%) 0.19 (0.081–0.267) 0.18 (0.027–1.07) 0.7352
Ratio of CD42/CD4+ iNKT cells 1.47 (1–3.56) 0.915 (0.11–3.4) 0.0826
Note. Data are shown as median (range), unless otherwise noted. HBV, hepatitis B virus; ALT, alanine aminotransferase; iNKT, invariant NKT cells. Comparisons of
different clinical characteristics between two groups were performed using the Mann-Whitney U test except the gender, which was tested by Fisher’s exact test.
doi:10.1371/journal.pone.0028871.t002
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0.993, P=0.04). A CD42/CD4+ iNKT cell ratio cutoff at
baseline of 0.94 gave the maximum combination of sensitivity
(100%) and specificity (58.33%) to predict HBeAg seroconversion
(Fig. 5B). Taken together, these data suggest that the ratio of
CD42/CD4+ iNKT cells in CHB patients at baseline is
associated with HBeAg seroconversion by week 52 after
telbivudine therapy, and has the potential to serve as a predictor
for HBeAg seroconversion.
Discussion
iNKT cells are a heterogeneous immune cell type that may be
involved in both the up- and down- regulation of a wide range of
immune reactions, including those to the hepatitis B virus [27,28].
In the context of HBV infection, the majority of iNKT cell
researches have been carried out in animals, and the behaviour of
these cells in humans with chronic HBV infection is poorly
understood. The purpose of this study was to test the hypothesis
that iNKT cells influence the clinical status of human subjects with
a chronic HBV infection. First, we conducted a cross-sectional
study to look for associations between iNKT cell subset frequencies
in PBMC and the clinical status of subjects with a chronic HBV
infection. Second we tested hypotheses relating to the possibility
that chronic hepatitis B is associated with the migration of iNKT
cells into the liver. Finally we looked for changes in iNKT cell
subset frequencies that were associated with and preceded changes
in clinical status in longitudinal data.
We first measured the proportion of circulating iNKT cells
cross-sectionally in CHB patients, healthy subjects and inactive
HBV healthy carriers. The frequency of circulating iNKT cells
was significantly decreased in CHB patients. De Lalla et al.
reported recently that the median percentage of peripheral
iNKT cells within total T cells was 0.09% in both chronic HBV-
and HCV- infected patients without cirrhosis, and 0.2% in
healthy donors. Our results are consistent with these findings
[21]. In contrast, Inoue et al. found no difference in frequency
of iNKT cells between patients with a chronic HCV infection
and healthy subjects [29]. These results suggest either that
iNKT cells have different roles in different viral infections or
that there are unknown differences in the populations of subjects
studied.
iNKT cells are phenotypically and functionally heterogeneous.
CD4+ iNKT cells are able to produce Th1 and Th2 cytokines
and tend to induce tolerance. By contrast, CD42 iNKT cells are
more likely to induce a Th1 response [26]. Therefore we
analyzed the variation of the two subsets of iNKT cells in CHB
patients, and found that the frequency of CD42 iNKT cells was
decreased in CHB, whereas the frequency of CD4+ iNKT cells
was similar to healthy subjects. As with Th1 and Th2 cells, it is
possible that there is a balance between CD4+ and CD42 iNKT
cells in healthy subjects, and the balance changes in various
clinical diseases, including chronic HBV infection. In the aspect
of cytokine-secretion, our data indicated that there was no
difference between CHB patients and HC in IFN-c and IL-4
production of circulating iNKT cells when stimulated with a-
GalCer or PMA. Snyder-Cappione JE et al. described recently
that the IFN-c response of circulating iNKT cells to a-GalCer
was impaired in HIV infected patients, suggesting the functions
of iNKT cells may be distinct among different virus infection
[24].
The precise mechanism of the decrease in circulating iNKT
cells in CHB patients remains unclear. Based on the report that
intrahepatic iNKT cells are dramatically enriched in chronically
inflamed livers as compared with noninflamed ones, we suppose
that the decrease in CHB patients is at least partly due to
trafficking to the liver [21]. The migration of circulating
leukocytes to sites of inflammation or injury is tightly directed
by chemokine and chemokine receptor interactions [30]. In
patients with chronic HCV infection, the expression of CCR1
and CCR5 on peripheral CD8+ T cells was lower and the
migration of CD8+ T cells in response to MIP-1a (CCL3), MIP-
1b (CCL4), and RANTES (CCL5) was significantly reduced
compared with healthy subjects [31]. In chronic HBV infection,
there are substantial numbers of virus-specific CD8 T cells, which
are barely detectable in the peripheral blood, infiltrated into the
liver [32,33]. It has been reported that cytotoxic T lymphocytes
specific for HBV, HCV or HIV-1 could release large quantity of
Figure 5. The ratio of CD42/CD4+ iNKT cells are associated
with HBeAg seroconversion. CHB patients who received telbivudine
(n=19) were divided into two groups according to the ratio of CD42/
CD4+ iNKT cells at baseline. (A) The number of patients achieving
HBeAg seroconversion in the high (.=1) and low (,1) ratio groups. (B)
Receiver operating characteristics (ROC) curve showing the relationship
between CD42/CD4+ iNKT cells and HBeAg seroconversion. * Fisher’s
exact test; # The ratio of CD42/CD4+ iNKT cells; & DeLong test; AUC,
Area under ROC curve; 95% CI, 95% confidence interval.
doi:10.1371/journal.pone.0028871.g005
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with viral antigen expressed on infected cells [34]. Considering
the high expression of CCR5 and CCR6 on circulating NKT
cells in CHB patients and the migration ability toward CCL5 in
vitro in our study, it’s reasonable to suppose that iNKT cells may
recruit to the liver in CHB patients, leading to the increased
proportion of intrahepatic iNKT cells and decreased proportion
of peripheral iNKT cells. Whereas in healthy control, there is no
inflammation and rare virus-specific CD8 T cells within the liver,
resulting in a relatively lower amount of intrahepatic chemokines
compared to the CHB patients. Consequently, although the
expression of CCR5 and CCR6 on iNKT cells is comparable
high with CHB patients, the recruitment of circulating iNKT
cells to the liver in healthy control is not as strong as that in CHB
patients, causing higher percentage of circulating iNKT cells in
HC indicated in our results.
There are very few studies in which changes in iNKT cell
frequency have been shown in longitudinal data from CHB
patients. The present study shows that the proportion of peripheral
iNKT cells in CHB patients was significantly increased at 52 weeks
after beginning telbivudine therapy, and approached the levels
found in inactive healthy carriers. Interestingly, only CD42 iNKT
cells increased at week 52, consisting with the results of cross-
sectional study that only CD42 iNKT cells decreased in CHB
patients. Thus both data suggest that there is an association
between control of the virus, whether as a result of host immunity
or antiviral therapy, and higher levels of iNKT cells. These data
also support our hypothesis that there is a balance between the
frequencies of CD4+ and CD42 iNKT cells, and viral clearance
will restore the balance which was altered by the chronic viral
infection.
Here, we show that the frequency of peripheral iNKT cells was
significantly decreased in patients with CHB relative to both
healthy controls and inactive healthy HBV carriers. Moreover,
the expressions of CCR5 and CCR6, whose ligands are
preferentially expressed in the liver, were significantly higher on
iNKT cells than that on conventional T cells. This may partially
explain why iNKT cells are enriched in the liver. In addition, the
low frequency of iNKT cells in CHB patients increased on
antiviral therapy. The ratio of CD42/CD4+ iNKT cells at
baseline was positively associated with HBeAg seroconversion
after 52 weeks antiviral therapy with telbivudine, and may be
useful as a predictor of HBeAg seroconversion on telbivudine
therapy in CHB patients.
Supporting Information
Figure S1 Correlations of iNKT cells with either HBV
DNA or ALT levels. The Spearman rank order correlation test
was used to evaluate the correlations of CD4+ iNKT cells (A, B),
CD42 iNKT cells (C, D) and the ratio of CD42/CD4+ iNKT
cells (E, F) with HBV DNA or ALT levels in CHB patients
(n=30).
(TIF)
Figure S2 The CCR5 and CCR6 expression on iNKT
cells between CHB patients and HC. The proportion of total
iNKT cells expressing CCR5 and CCR6 in CHB patients (n=6)
was compared with HC subjects (n=10) using Mann-Whitney U
test. NS means no significance.
(TIF)
Figure S3 The dynamic changes of iNKT cells in CHB
patients during therapy. Nineteen CHB patients received anti-
viral therapy with telbivudine were divided into two groups,
seroconversion (n=7) and Non-seroconversion (n=12), depending
on the achievement of HBeAg seroconversion at week 52. The
dynamic changes of HBV DNA and ALT levels (A,B), total, CD42
and CD4+ iNKT cells (C–E), and the ratio of CD42/CD4+ iNKT
cells (F) at different time points were compared between two groups.
*P,0.05, **P,0.01, using repeated measures two-way ANOVA
followed by Bonferroni post-tests.
(TIF)
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